WEBULL

Takeda Zasocitinib Phase 3 Plaque Psoriasis Studies Meet Primary And Ranked Secondary Endpoints, With PASI 90 And PASI 100 Clear Skin Results By Week 16

Benzinga · 2d ago
  • Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis
  • More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16
  • Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies